{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,4]],"date-time":"2026-01-04T02:34:14Z","timestamp":1767494054573,"version":"3.48.0"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,3]]},"DOI":"10.7759\/cureus.100713","type":"journal-article","created":{"date-parts":[[2026,1,4]],"date-time":"2026-01-04T02:31:53Z","timestamp":1767493913000},"source":"Crossref","is-referenced-by-count":0,"title":["Remarkable Response to Etoposide and Cisplatin in Aggressive-Variant Prostate Cancer With Low Prostate-Specific Antigen Levels: A Case Report"],"prefix":"10.7759","author":[{"given":"Junichi","family":"Ikeda","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hisanori","family":"Taniguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monta","family":"Inoue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuki","family":"Masuo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahiro","family":"Nakamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaaki","family":"Yanishi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katsunori","family":"Uchida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hidefumi","family":"Kinoshita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa031918","article-title":"Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter","volume":"350","author":"Thompson IM","year":"2004","unstructured":"Thompson IM, Pauler DK, Goodman PJ, et al.. Prevalence of prostate cancer among men with a prostate-specific antigen level &lt; or =4.0 ng per milliliter. N Engl J Med. 2004, 350:2239-46. 10.1056\/NEJMoa031918","journal-title":"N Engl J Med"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/s0022-5347(17)38972-3","article-title":"Clinical use of prostate specific antigen in patients with prostate cancer","volume":"142","author":"Hudson MA","year":"1989","unstructured":"Hudson MA, Bahnson RR, Catalona WJ. Clinical use of prostate specific antigen in patients with prostate cancer. J Urol. 1989, 142:1011-7. 10.1016\/s0022-5347(17)38972-3","journal-title":"J Urol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2018.01.043","article-title":"Clinical and genomic characterization of low-prostate-specific antigen, high-grade prostate cancer","volume":"74","author":"Mahal BA","year":"2018","unstructured":"Mahal BA, Yang DD, Wang NQ, et al.. Clinical and genomic characterization of low-prostate-specific antigen, high-grade prostate cancer. Eur Urol. 2018, 74:146-54. 10.1016\/j.eururo.2018.01.043","journal-title":"Eur Urol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-1259","article-title":"Combined tumor suppressor defects characterize clinically defined aggressive variant prostate cancers","volume":"22","author":"Aparicio AM","year":"2016","unstructured":"Aparicio AM, Shen L, Tapia EL, et al.. Combined tumor suppressor defects characterize clinically defined aggressive variant prostate cancers. Clin Cancer Res. 2016, 22:1520-30. 10.1158\/1078-0432.CCR-15-1259","journal-title":"Clin Cancer Res"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30408-5","article-title":"Cabazitaxel plus carboplatin for the treatment of men with metastatic castration-resistant prostate cancers: a randomised, open-label, phase 1-2 trial","volume":"20","author":"Corn PG","year":"2019","unstructured":"Corn PG, Heath EI, Zurita A, et al.. Cabazitaxel plus carboplatin for the treatment of men with metastatic castration-resistant prostate cancers: a randomised, open-label, phase 1-2 trial. Lancet Oncol. 2019, 20:1432-43. 10.1016\/S1470-2045(19)30408-5","journal-title":"Lancet Oncol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-021-02230-y","article-title":"Systematic review and meta-analysis of the diagnostic accuracy of prostate-specific antigen (PSA) for the detection of prostate cancer in symptomatic patients","volume":"20","author":"Merriel SW","year":"2022","unstructured":"Merriel SW, Pocock L, Gilbert E, Creavin S, Walter FM, Spencer A, Hamilton W. Systematic review and meta-analysis of the diagnostic accuracy of prostate-specific antigen (PSA) for the detection of prostate cancer in symptomatic patients. BMC Med. 2022, 20:54. 10.1186\/s12916-021-02230-y","journal-title":"BMC Med"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19870515)59:10<1803::aid-cncr2820591019>3.0.co;2-x","article-title":"Small cell carcinoma of the prostate. Part I. A clinicopathologic study of 20 cases","volume":"59","author":"T\u00eatu B","year":"1987","unstructured":"T\u00eatu B, Ro JY, Ayala AG, Johnson DE, Logothetis CJ, Ordonez NG. Small cell carcinoma of the prostate. Part I. A clinicopathologic study of 20 cases. Cancer. 1987, 59:1803-9. 10.1002\/1097-0142(19870515)59:10&lt;1803::aid-cncr2820591019&gt;3.0.co;2-x","journal-title":"Cancer"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1096-9896(199910)189:2<219::AID-PATH423>3.0.CO;2-F","article-title":"Androgen receptor gene amplification increases tissue PSA protein expression in hormone-refractory prostate carcinoma","volume":"189","author":"Koivisto PA","year":"1999","unstructured":"Koivisto PA, Helin HJ. Androgen receptor gene amplification increases tissue PSA protein expression in hormone-refractory prostate carcinoma. J Pathol. 1999, 189:219-23. 10.1002\/(SICI)1096-9896(199910)189:2&lt;219::AID-PATH423&gt;3.0.CO;2-F","journal-title":"J Pathol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1172\/JCI186599","article-title":"Patterns of intra- and intertumor phenotypic heterogeneity in lethal prostate cancer","volume":"135","author":"Roudier MP","year":"2025","unstructured":"Roudier MP, Gulati R, Sayar E, et al.. Patterns of intra- and intertumor phenotypic heterogeneity in lethal prostate cancer. J Clin Invest. 2025, 135:e186599. 10.1172\/JCI186599","journal-title":"J Clin Invest"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-1587","article-title":"Transcriptomic heterogeneity of androgen receptor activity defines a de novo low AR-active subclass in treatment na\u00efve primary prostate cancer","volume":"25","author":"Spratt DE","year":"2019","unstructured":"Spratt DE, Alshalalfa M, Fishbane N, et al.. Transcriptomic heterogeneity of androgen receptor activity defines a de novo low AR-active subclass in treatment na\u00efve primary prostate cancer. Clin Cancer Res. 2019, 25:6721-30. 10.1158\/1078-0432.CCR-19-1587","journal-title":"Clin Cancer Res"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.40787","article-title":"Mortality risk for docetaxel-treated, high-grade prostate cancer with low PSA levels: a meta-analysis","volume":"6","author":"Mahal BA","year":"2023","unstructured":"Mahal BA, Kwak L, Xie W, et al.. Mortality risk for docetaxel-treated, high-grade prostate cancer with low PSA levels: a meta-analysis. JAMA Netw Open. 2023, 6:e2340787. 10.1001\/jamanetworkopen.2023.40787","journal-title":"JAMA Netw Open"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-12-3791","article-title":"Platinum-based chemotherapy for variant castrate-resistant prostate cancer","volume":"19","author":"Aparicio AM","year":"2013","unstructured":"Aparicio AM, Harzstark AL, Corn PG, et al.. Platinum-based chemotherapy for variant castrate-resistant prostate cancer. Clin Cancer Res. 2013, 19:3621-30. 10.1158\/1078-0432.CCR-12-3791","journal-title":"Clin Cancer Res"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/449278-remarkable-response-to-etoposide-and-cisplatin-in-aggressive-variant-prostate-cancer-with-low-prostate-specific-antigen-levels-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,4]],"date-time":"2026-01-04T02:31:54Z","timestamp":1767493914000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/449278-remarkable-response-to-etoposide-and-cisplatin-in-aggressive-variant-prostate-cancer-with-low-prostate-specific-antigen-levels-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,3]]},"references-count":12,"URL":"https:\/\/doi.org\/10.7759\/cureus.100713","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1,3]]}}}